Jagsonpal [JAGSNPHARM] vs Divi's Laboratories [DIVISLAB] Detailed Stock Comparison
Jagsonpal
NSE
Loading...
Divi's Laboratories
NSE
Loading...
TLDR: Quick Comparison Summary
Based on 20 vital metrics comparison: Jagsonpal wins in 11 metrics, Divi's Laboratories wins in 9 metrics, with 0 ties. Jagsonpal appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Jagsonpal | Divi's Laboratories | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 27.17 | 70.42 | Jagsonpal |
| Price-to-Book Ratio | 6.86 | 10.88 | Jagsonpal |
| Debt-to-Equity Ratio | 3.85 | 0.03 | Divi's Laboratories |
| PEG Ratio | 0.26 | 2.66 | Jagsonpal |
| EV/EBITDA | 27.56 | 51.97 | Jagsonpal |
| Profit Margin (TTM) | 21.50% | 23.89% | Divi's Laboratories |
| Operating Margin (TTM) | 15.69% | 25.60% | Divi's Laboratories |
| EBITDA Margin (TTM) | 15.69% | 25.60% | Divi's Laboratories |
| Return on Equity | 23.07% | 14.64% | Jagsonpal |
| Return on Assets (TTM) | 19.90% | 12.94% | Jagsonpal |
| Free Cash Flow (TTM) | $549.52M | $2.15B | Divi's Laboratories |
| Dividend Yield | 0.36% | 0.91% | Divi's Laboratories |
| 1-Year Return | 73.41% | 32.34% | Jagsonpal |
| Price-to-Sales Ratio (TTM) | 5.78 | 16.87 | Jagsonpal |
| Enterprise Value | $15.34B | $1,592.76B | Divi's Laboratories |
| EV/Revenue Ratio | 5.42 | 16.50 | Jagsonpal |
| Gross Profit Margin (TTM) | 64.39% | 60.33% | Jagsonpal |
| Revenue per Share (TTM) | $42 | $363 | Divi's Laboratories |
| Earnings per Share (Diluted) | $9.02 | $87.08 | Divi's Laboratories |
| Beta (Stock Volatility) | 0.24 | 0.27 | Jagsonpal |
Performance
Key Stats
Valuation
Financials
Short Interest
Dividends
Jagsonpal vs Divi's Laboratories Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Jagsonpal | 1.80% | -8.58% | -3.15% | 12.42% | 6.68% | -5.64% |
| Divi's Laboratories | 0.52% | 0.02% | -9.53% | -1.34% | 4.94% | 0.98% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Jagsonpal | 73.41% | 60.97% | 1,380.07% | 1,658.25% | 2,229.85% | 1,534.00% |
| Divi's Laboratories | 32.34% | 65.91% | 88.85% | 402.68% | 1,538.26% | 8,472.13% |
Performance & Financial Health Analysis: Jagsonpal vs Divi's Laboratories
| Metric | JAGSNPHARM | DIVISLAB |
|---|---|---|
| Market Information | ||
| Market Cap | ₹16.35B | ₹1.63T |
| Market Cap Category | Small cap | Large cap |
| 10 Day Avg. Volume | 214,853 | 568,365 |
| 90 Day Avg. Volume | 586,150 | 368,116 |
| Last Close | ₹249.50 | ₹6,164.50 |
| 52 Week Range | ₹141.06 - ₹328.04 | ₹4,615.55 - ₹7,071.50 |
| % from 52W High | -23.94% | -12.83% |
| All-Time High | ₹328.04 (Nov 25, 2024) | ₹7,071.50 (Jul 08, 2025) |
| % from All-Time High | -23.94% | -12.83% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 0.23% | 0.14% |
| Quarterly Earnings Growth | 1.03% | 0.27% |
| Financial Health | ||
| Profit Margin (TTM) | 0.22% | 0.24% |
| Operating Margin (TTM) | 0.16% | 0.26% |
| Return on Equity (TTM) | 0.23% | 0.15% |
| Debt to Equity (MRQ) | 3.85 | 0.03 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | ₹35.72 | ₹563.87 |
| Cash per Share (MRQ) | ₹19.08 | ₹132.86 |
| Operating Cash Flow (TTM) | ₹532.93M | ₹19.67B |
| Levered Free Cash Flow (TTM) | ₹553.61M | ₹21.91B |
| Dividends | ||
| Last 12-Month Dividend Yield | 0.36% | 0.91% |
| Last 12-Month Dividend | ₹0.80 | ₹60.00 |
Valuation & Enterprise Metrics Analysis: Jagsonpal vs Divi's Laboratories
| Metric | JAGSNPHARM | DIVISLAB |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 27.17 | 70.42 |
| Forward P/E | N/A | 108.93 |
| PEG Ratio | 0.26 | 2.66 |
| Price to Sales (TTM) | 5.78 | 16.87 |
| Price to Book (MRQ) | 6.86 | 10.88 |
| Market Capitalization | ||
| Market Capitalization | ₹16.35B | ₹1.63T |
| Enterprise Value | ₹15.34B | ₹1.59T |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 5.42 | 16.50 |
| Enterprise to EBITDA | 27.56 | 51.97 |
| Risk & Other Metrics | ||
| Beta | 0.24 | 0.27 |
| Book Value per Share (MRQ) | ₹35.72 | ₹563.87 |
Financial Statements Comparison: Jagsonpal vs Divi's Laboratories
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | JAGSNPHARM | DIVISLAB |
|---|---|---|
| Revenue/Sales | ₹756.12M | ₹24.10B |
| Cost of Goods Sold | ₹269.27M | ₹9.56B |
| Gross Profit | ₹486.85M | ₹14.54B |
| Research & Development | N/A | N/A |
| Operating Income (EBIT) | ₹118.60M | ₹6.17B |
| EBITDA | ₹170.38M | ₹8.48B |
| Pre-Tax Income | ₹144.31M | ₹7.33B |
| Income Tax | ₹36.36M | ₹1.88B |
| Net Income (Profit) | ₹107.95M | ₹5.45B |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | JAGSNPHARM | DIVISLAB |
|---|---|---|
| Cash & Equivalents | ₹112.15M | ₹4.15B |
| Total Current Assets | ₹1.61B | ₹100.81B |
| Total Current Liabilities | ₹259.04M | ₹14.52B |
| Long-Term Debt | ₹76.32M | ₹20.00M |
| Total Shareholders Equity | ₹2.40B | ₹149.69B |
| Retained Earnings | N/A | ₹134.00B |
| Property, Plant & Equipment | ₹88.37M | ₹3.19B |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | JAGSNPHARM | DIVISLAB |
|---|---|---|
| Operating Cash Flow | N/A | N/A |
| Capital Expenditures | N/A | N/A |
| Free Cash Flow | N/A | N/A |
| Debt Repayment | N/A | N/A |
| Common Stock Repurchase | N/A | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | JAGSNPHARM | DIVISLAB |
|---|---|---|
| Shares Short | N/A | N/A |
| Short Ratio | N/A | N/A |
| Short % of Float | N/A | N/A |
| Average Daily Volume (10 Day) | 214,853 | 568,365 |
| Average Daily Volume (90 Day) | 586,150 | 368,116 |
| Shares Outstanding | 66.40M | 265.47M |
| Float Shares | 16.17M | 120.74M |
| % Held by Insiders | 0.76% | 0.52% |
| % Held by Institutions | 0.03% | 0.29% |
Dividend Analysis & Yield Comparison: Jagsonpal vs Divi's Laboratories
| Metric | JAGSNPHARM | DIVISLAB |
|---|---|---|
| Last 12-Month Dividend | ₹0.80 | ₹60.00 |
| Last 12-Month Dividend Yield | 0.36% | 0.91% |
| 3-Year Avg Annual Dividend | ₹0.27 | ₹50.00 |
| 3-Year Avg Dividend Yield | 0.49% | 0.70% |
| 3-Year Total Dividends | ₹0.80 | ₹150.00 |
| Ex-Dividend Date | Sep 06, 2024 | Jul 25, 2025 |